Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Nail unit involvement during severe initial pemphigus vulgaris development..
Eur J Dermatol. 19(3), 290-1.
(2009). Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial..
Clin J Pain. 29(10), 857-64.
(2013). Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma..
Br J Dermatol. 170(4), 809-15.
(2014). Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study..
Br J Dermatol. 162(1), 171-5.
(2010). Stellate erosion: the dermoscopic Nikolsky sign?.
Eur J Dermatol. 27(6), 659-660.
(2017). Effect of pigmentation on photodynamic therapy..
Lancet Oncol. 14(9), e339-40.
(2013). Histopathological study of perilesional skin in patients diagnosed with nonmelanoma skin cancer..
Clin Exp Dermatol. 41(1), 21-5.
(2016). Farmers develop more aggressive histologic subtypes of basal cell carcinoma. Experience from a Tertiary Hospital in Northern Greece..
J Eur Acad Dermatol Venereol. 30 Suppl 3, 17-20.
(2016). Clinicopathologically problematic melanocytic tumors: a case-based review..
Dermatol Pract Concept. 8(4), 306-313.
(2018). Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study..
Eur Urol. 56(6), 937-47.
(2009). Prevention of blood-transfusion-induced impairment of anastomotic healing by leucocyte depletion in rats..
Eur J Surg. 166(7), 562-7.
(2000). How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2..
Neurourol Urodyn. 36(4), 869-875.
(2017). Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014..
Neurourol Urodyn. 35(2), 293-8.
(2016). Words of wisdom. Re: Intrathecal administration of botulinum toxin type a improves urinary bladder function and reduces pain in rats with cystitis..
Eur Urol. 67(4), 816.
(2015). Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?.
World J Urol. 37(12), 2811-2812.
(2019). Changes in the lipid profile of elite basketball and soccer players after a match..
Res Sports Med. 22(1), 100-10.
(2014). Is there "brain OAB" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017..
Neurourol Urodyn. 37(S4), S38-S45.
(2018). Neurourological Management After Failed Intradetrusor OnabotulinumtoxinA Injections..
Eur Urol Focus. 6(5), 814-816.
(2020). Hematemesis, a very rare presentation of solid pseudo-papillary tumors of the pancreas: a case report..
J Med Case Rep. 2, 271.
(2008). Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?.
BJU Int. 120(4), 459-460.
(2017). Intravesical Botox for overactive bladder; how to minimize complications and manage failures..
Curr Drug Targets.
(2020). Male lower urinary tract symptoms: a riddle waiting to be solved..
Eur Urol. 64(3), 408-10.
(2013). Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures.
Current Drug Targets. 21(15), 1527 - 1536.
(2020). An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity..
World J Urol. 31(6), 1469-74.
(2013). Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?.
Curr Drug Targets. 16(11), 1187-97.
(2015).